-
1Academic Journal
المؤلفون: Masanori Tokumoto (9318435), Shin Tokunaga (5052263), Shinji Asada (6751478), Yuichi Endo (153595), Noriaki Kurita (752035), Masafumi Fukagawa (721664), Tadao Akizawa (316095)
مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Physiology, Pharmacology, Immunology, Cancer, Science Policy, Hematology, Infectious Diseases, Virology, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, 79 %, medium, 58 %, respectively, 5 – 6, serum intact pth, prior cinacalcet use, div >< p, 92 patients ]), final evocalcet dosages, dependent safety concerns, higher serum levels, target pth levels, dose evocalcet (<, target range, final high, dependent efficacy
-
2Academic Journal
المؤلفون: Masanori Tokumoto (9318435), Shin Tokunaga (5052263), Shinji Asada (6751478), Yuichi Endo (153595), Noriaki Kurita (752035), Masafumi Fukagawa (721664), Tadao Akizawa (316095)
مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Physiology, Pharmacology, Immunology, Cancer, Science Policy, Hematology, Infectious Diseases, Virology, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, 79 %, medium, 58 %, respectively, 5 – 6, serum intact pth, prior cinacalcet use, div >< p, 92 patients ]), final evocalcet dosages, dependent safety concerns, higher serum levels, target pth levels, dose evocalcet (<, target range, final high, dependent efficacy
-
3Academic Journal
المؤلفون: Masanori Tokumoto (9318435), Shin Tokunaga (5052263), Shinji Asada (6751478), Yuichi Endo (153595), Noriaki Kurita (752035), Masafumi Fukagawa (721664), Tadao Akizawa (316095)
مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Physiology, Pharmacology, Immunology, Cancer, Science Policy, Hematology, Infectious Diseases, Virology, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, 79 %, medium, 58 %, respectively, 5 – 6, serum intact pth, prior cinacalcet use, div >< p, 92 patients ]), final evocalcet dosages, dependent safety concerns, higher serum levels, target pth levels, dose evocalcet (<, target range, final high, dependent efficacy
-
4Academic Journal
المؤلفون: Masanori Tokumoto (9318435), Shin Tokunaga (5052263), Shinji Asada (6751478), Yuichi Endo (153595), Noriaki Kurita (752035), Masafumi Fukagawa (721664), Tadao Akizawa (316095)
مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Physiology, Pharmacology, Immunology, Cancer, Science Policy, Hematology, Infectious Diseases, Virology, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, 79 %, medium, 58 %, respectively, 5 – 6, serum intact pth, prior cinacalcet use, div >< p, 92 patients ]), final evocalcet dosages, dependent safety concerns, higher serum levels, target pth levels, dose evocalcet (<, target range, final high, dependent efficacy
-
5Academic Journal
المؤلفون: Nao Oguro (11583553), Ryo Suzuki (138376), Nobuyuki Yajima (3364), Kosuke Sakurai (11583556), Takafumi Wakita (457602), Mark A. Hall (2230987), Noriaki Kurita (752035)
مصطلحات موضوعية: Medicine, Science Policy, Mental Health, Japan, Non-communicable disease, Medical care, Physicians, Physician trust, Dissatisfaction, Family experience
-
6Academic Journal
المؤلفون: Nao Oguro (11583553), Ryo Suzuki (138376), Nobuyuki Yajima (3364), Kosuke Sakurai (11583556), Takafumi Wakita (457602), Mark A. Hall (2230987), Noriaki Kurita (752035)
مصطلحات موضوعية: Medicine, Science Policy, Mental Health, Japan, Non-communicable disease, Medical care, Physicians, Physician trust, Dissatisfaction, Family experience
-
7Academic Journal
المؤلفون: Nao Oguro (11583553), Ryo Suzuki (138376), Nobuyuki Yajima (3364), Kosuke Sakurai (11583556), Takafumi Wakita (457602), Mark A. Hall (2230987), Noriaki Kurita (752035)
مصطلحات موضوعية: Medicine, Science Policy, Mental Health, Japan, Non-communicable disease, Medical care, Physicians, Physician trust, Dissatisfaction, Family experience
-
8Academic Journal
المؤلفون: Nao Oguro (11583553), Ryo Suzuki (138376), Nobuyuki Yajima (3364), Kosuke Sakurai (11583556), Takafumi Wakita (457602), Mark A. Hall (2230987), Noriaki Kurita (752035)
مصطلحات موضوعية: Medicine, Science Policy, Mental Health, Japan, Non-communicable disease, Medical care, Physicians, Physician trust, Dissatisfaction, Family experience
-
9Image
المؤلفون: Masanori Tokumoto (9318435), Shin Tokunaga (5052263), Shinji Asada (6751478), Yuichi Endo (153595), Noriaki Kurita (752035), Masafumi Fukagawa (721664), Tadao Akizawa (316095)
مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Physiology, Pharmacology, Immunology, Cancer, Science Policy, Hematology, Infectious Diseases, Virology, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, 79 %, medium, 58 %, respectively, 5 – 6, serum intact pth, prior cinacalcet use, div >< p, 92 patients ]), final evocalcet dosages, dependent safety concerns, higher serum levels, target pth levels, dose evocalcet (<, target range, final high, dependent efficacy
-
10Image
المؤلفون: Masanori Tokumoto (9318435), Shin Tokunaga (5052263), Shinji Asada (6751478), Yuichi Endo (153595), Noriaki Kurita (752035), Masafumi Fukagawa (721664), Tadao Akizawa (316095)
مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Physiology, Pharmacology, Immunology, Cancer, Science Policy, Hematology, Infectious Diseases, Virology, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, 79 %, medium, 58 %, respectively, 5 – 6, serum intact pth, prior cinacalcet use, div >< p, 92 patients ]), final evocalcet dosages, dependent safety concerns, higher serum levels, target pth levels, dose evocalcet (<, target range, final high, dependent efficacy
-
11Image
المؤلفون: Masanori Tokumoto (9318435), Shin Tokunaga (5052263), Shinji Asada (6751478), Yuichi Endo (153595), Noriaki Kurita (752035), Masafumi Fukagawa (721664), Tadao Akizawa (316095)
مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Physiology, Pharmacology, Immunology, Cancer, Science Policy, Hematology, Infectious Diseases, Virology, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, 79 %, medium, 58 %, respectively, 5 – 6, serum intact pth, prior cinacalcet use, div >< p, 92 patients ]), final evocalcet dosages, dependent safety concerns, higher serum levels, target pth levels, dose evocalcet (<, target range, final high, dependent efficacy
-
12
المؤلفون: Masanori Tokumoto (9318435), Shin Tokunaga (5052263), Shinji Asada (6751478), Yuichi Endo (153595), Noriaki Kurita (752035), Masafumi Fukagawa (721664), Tadao Akizawa (316095)
مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Physiology, Pharmacology, Immunology, Cancer, Science Policy, Hematology, Infectious Diseases, Virology, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, 79 %, medium, 58 %, respectively, 5 – 6, serum intact pth, prior cinacalcet use, div >< p, 92 patients ]), final evocalcet dosages, dependent safety concerns, higher serum levels, target pth levels, dose evocalcet (<, target range, final high, dependent efficacy
-
13
المؤلفون: Masanori Tokumoto (9318435), Shin Tokunaga (5052263), Shinji Asada (6751478), Yuichi Endo (153595), Noriaki Kurita (752035), Masafumi Fukagawa (721664), Tadao Akizawa (316095)
مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Physiology, Pharmacology, Immunology, Cancer, Science Policy, Hematology, Infectious Diseases, Virology, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, 79 %, medium, 58 %, respectively, 5 – 6, serum intact pth, prior cinacalcet use, div >< p, 92 patients ]), final evocalcet dosages, dependent safety concerns, higher serum levels, target pth levels, dose evocalcet (<, target range, final high, dependent efficacy